Estimated cases of blindness and visual impairment from neovascular age-related macular degeneration avoided in Australia by ranibizumab treatment

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mitchell, Paul ^a   Bressler, Neil ^b   Doan, Quan V ^c   Dolan, Chantal ^d   Ferreira, Alberto ^e   Osborne, Aaron ^e,i   Rochtchina, Elena ^a   Danese, Mark ^c   Colman, Shoshana ^f   Wong, Tien Y ^g,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Outcomes Insights Inc   (United States)

^d CMD Consulting Inc   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f GENENTECH INC   (United States)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; AUSTRALIA; BLINDNESS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EYE PROTECTION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VISUAL ACUITY; VISUAL IMPAIRMENT; COMPLICATION; MACULAR DEGENERATION; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; BLINDNESS; FEMALE; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84903641540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101072     Document Type: Article

References (31)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379: 1728-1738.
2. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844-851.
3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, et al. (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57-65.
4. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Eng J Med 355: 1419-1431.
6. Cheung N, Wong TY (2012) Changing trends of blindness: the initial harvest from translational public health and clinical research in ophthalmology. Am J Ophthalmol 153: 193-195.
7. Bloch SB, Larsen M, Munch IC (2012) Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153: 209-213 e202.
8. Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O (2012) Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 153: 214-221 e211.
9. Bressler NM, Doan QV, Varma R, Lee PP, Suner IJ, et al. (2011) Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 129: 709-717.
10. Campbell JP, Bressler SB, Bressler NM (2012) Impact of availability of antivascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 130: 794-795.
11. Australian Institute of Health and Welfare (2005) Vision problems among older Australians. Bulletin no. 27. AIHW cat. No. AUS 60. Canberra. 2005. Accessed September 2013. Available: http://www.aihw.gov.au/WorkArea/ DownloadAsset.aspx?id=6442453394.
12. Macular Degeneration Foundation (2011) Eyes on the future. Accessed September 2013. Available: http://www.mdfoundation.com.au/LatestNews/Deloitte- Eyes-on-the-Future-Report-Exec-Summary%20web.pdf.
13. Wang JJ, Rochtchina E, Lee AJ, Chia EM, Smith W, et al. (2007) Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 114: 92-98.
14. Bressler NM, Bressler SB, Congdon NG, Ferris FL, 3rd, Friedman DS, et al. (2003) Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121: 1621-1624.
15. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, et al. (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857.
16. Australian Bureau of Statistics (2010) 3201.0 Population by Age and Sex, Australian States and Territories. Accessed September 2013. Available: http://www.abs.gov.au/ausstats/absat.nsf/mf/3201.0/.
17. Australian Bureau of Statistics (2010) 3302.0 - Deaths, Australia, 2009; Table 2: Death rates, Summary, States and territories - 1999 to 2009. 2010. Accessed September 2013. Available: http://www.abs.gov.au/ausstats/absat.nsf/ detailspage/3302.02009.
18. Commonwealth of Australia (2011) Guide to Social Security Law. 7 Jan 2011. Accessed September 2013. Available: http://www.facsia.gov.au/guides-acts/ ssg/ssguide-1/ssguide-1.1/ssguide-1.1.p/ssguide-1.1.p.210.html.
19. Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH (2014) Anti- VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina Epub ahead of print.
20. Gillies MC, Walton RJ, Arnold JJ, McAllister IL, Simpson JM, et al. (2014) Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort. Ophthalmology 121: 676-681.
21. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group (2014) The Neovascular Age-Related Macular Degeneration Database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121: 1092-1101.
22. Cruess A, Zlateva G, Xu X, Rochon S (2007) Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol 42: 836-843.
23. Hochberg C, Maul E, Chan ES, Van Landingham S, Ferrucci L, et al. (2012) Association of vision loss in glaucoma and age-related macular degeneration with IADL disability. Invest Ophthalmol Vis Sci 53: 3201-3206.
24. Ivers RQ, Cumming RG, Mitchell P, Attebo K (1998) Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 46: 58-64.
25. Klein BE, Moss SE, Klein R, Lee KE, Cruickshanks KJ (2003) Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. Ophthalmology 110: 644-650.
26. Lotery A, Xu X, Zlatava G, Loftus J (2007) Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study. Br J Ophthalmol 91: 1303-1307.
27. Popescu ML, Boisjoly H, Schmaltz H, Kergoat MJ, Rousseau J, et al. (2011) Age-related eye disease and mobility limitations in older adults. Invest Ophthalmol Vis Sci 52: 7168-7174.
28. Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Mones J, et al. (2007) Burden and health care resource utilization in neovascular age-related macular degeneration: Findings of a multicountry study. Arch Ophthalmol 125: 1249-1254.
29. Szabo SM, Janssen PA, Khan K, Lord SR, Potter MJ (2010) Neovascular AMD: an overlooked risk factor for injurious falls. Osteoporos Int 21: 855-862.
30. Wood JM, Lacherez P, Black AA, Cole MH, Boon MY, et al. (2011) Risk of falls, injurious falls, and other injuries resulting from visual impairment among older adults with age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 5088-5092.
31. Mitchell P, Wang JJ, Foran S, Smith W (2002) Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 109: 1092-1097.